《大行報告》匯豐研究下調創科(00669.HK)目標價至151元 評級「買入」
匯豐研究發表報告,指創科實業(00669.HK)股價表現應大致反映美國樓市疲弱,但相對於2018年的市盈率谷底仍有12.6%的下行空間;然而預計公司戶外動力設備和Milwaukee將繼續推動收入增長,預計今年將按年增長15%。該行維持創科「買入」評級,但將目標價從165元下調至151元。
報告認為,市場已經消化了按揭貸款利率上升的影響,創科的市盈率預測從今年1月的22.9倍降至18.9倍。今年2月,美國新屋動工和完工之間的差距擴大到643,000套,這是新屋動工超過完工的第17個月,這表明持續的供應鏈緊張並未得到緩解,又指樓價上升亦影響美國的樓市需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.